Recenti progressi in medicina最新文献_第6页

[Clinical decision rules for chest pain in primary care are supported by weak evidence and are difficult to apply.] [初级保健胸痛的临床决策规则证据不足，难以应用。]

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44119

Viviana Forte, Henry Barry, Peter K Kurotschka

引用次数: 0

[Continuous beta-blockers after acute myocardial infarction: fewer hospitalizations, but no effect on mortality or major cardiovascular or cerebrovascular events.] [急性心肌梗死后持续使用-受体阻滞剂：住院次数减少，但对死亡率或主要心脑血管事件无影响]

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44117

Viviana Forte, Mark H Ebell, Peter K Kurotschka

引用次数: 0

[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa.] CAR-T治疗老年复发/难治性弥漫性大b细胞淋巴瘤热那亚圣马蒂诺医院临床病例

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44127

Chiara Ghiggi

{"title":"[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa.]","authors":"Chiara Ghiggi","doi":"10.1701/4416.44127","DOIUrl":"10.1701/4416.44127","url":null,"abstract":"CAR-T therapy (chimeric antigen receptor T-cell) has revolutionized the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) that have relapsed or are refractory to conventional chemotherapies. In particular, patients who have relapsed or are refractory to two lines of therapy are patients who have a poor prognosis. The advent of CAR-T immunotherapy is an innovative approach with which we can give hope of recovery even in the case of refractory disease, even for patients who are not candidates for high-dose therapies, for example due to age. Here we present a clinical case of a 74-year-old patient at second relapse, refractory to two lines of chemotherapy and subjected to third-line CAR-T with axicabtagene ciloleucel, after a good response to bridge therapy with rituximab polatuzumab and bendamustine (RPB). Complete remission of the disease still persists eleven months after treatment. Tolerance to CAR-T was excellent, with grade 1 cytokine release syndrome (CRS), no neurological complications (ICANS-immune effector cell-associated neurotoxicity syndrome) and no infectious complications. Severe hypogammaglobulinemia persists eleven months after CAR-T reinfusion, for which he still performs immunoglobulin replenishment for prophylactic purposes.","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"12e-14e"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pseudoprogression after CAR-T cell therapy: friend or foe?.] CAR-T细胞治疗后的假性进展：是敌是友？

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44125

Ilaria Cutini

{"title":"[Pseudoprogression after CAR-T cell therapy: friend or foe?.]","authors":"Ilaria Cutini","doi":"10.1701/4416.44125","DOIUrl":"10.1701/4416.44125","url":null,"abstract":"Introduction: Pseudoprogression is a complication observed following CAR-T therapy that can mimic disease progression; however, its incidence is not well defined. This phenomenon is driven by a robust inflammatory response due to the recognition of CAR-T cells targeting the lymphoma. Misinterpreting pseudoprogression as true disease progression could result in unnecessary alterations to the treatment regimen.Clinical case: Here, we present a case of a 69-year-old patient with diffuse large B-cell lymphoma (DLBCL) who received axicabtagene ciloleucel as fourth line therapy and exhibited pseudoprogression on Pet scans at 3 and 9 months after treatment. Two biopsies performed to investigate these findings were negative for lymphoma recurrence. The patient has been in complete metabolic remission for three years following the infusion.Conclusions: Biopsy is crucial for distinguishing between pseudoprogression and disease progression in patients with DLBCL after CAR-T therapy. However, obtaining a biopsy may be challenging when lesions are closed to vital organs or major blood vessels, complicating the procedure and increasing the risk of complications.","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"4e-7e"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cena di Natale. 圣诞晚餐。

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44122

Fabio De Iaco

引用次数: 0

In questo numero
2025 Gennaio. 这个数字是2025年1月。

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44111

引用次数: 0

Recensione
“Codice Rosso”. 红色代码评论。

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44123

Stefano Cagliano

引用次数: 0

["For their own good". Medical assistance in dying: a right for whom?] “为了他们自己好。”死亡时的医疗援助：谁有权利？］

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44115

Giuseppe R Gristina

{"title":"[\"For their own good\". Medical assistance in dying: a right for whom?]","authors":"Giuseppe R Gristina","doi":"10.1701/4416.44115","DOIUrl":"10.1701/4416.44115","url":null,"abstract":"Background: The admission criteria to the medical assistance in dying (MAID) procedures (Euthanasia - E; Physician Assisted Suicide - PAS) represent a much debated issue. In most of the jurisdictions where MAID is legal, the unbearable suffering due to a terminal illness constitues the main admission condition. In contrast, those suffering from either a mental disorder or an existential discomfort are excluded. Some consider the exclusion of the former group to be protective towards those deemed vulnerable because they are not able to make free and informed decisions, while the latter is excluded to align the legal approaches to the prevailing moral models. Others consider these stances discrimination.Purpose: To prove that when someone requests MAID, his suffering should be first and foremost investigated not only and not so much for its causes, but, above all, for its key role played in understanding the MAID request.Contents: After reviewing the specific aspects of suffering in relation to his three determinants - existential suffering, mental disorder, terminal illness - the article provides the evidence that: a) such a conditions, although completely different from each other, share the same psychological processes leading to the unbeaerable suffering and then to the request for MAID or to the suicide ideation/completion; b) there is no scientific data supporting a discrimination access to MAID on the basis of the presence/absence of a terminal illness.Conclusions: Using the unbearable suffering due to a terminal illness as the sole criterion for admission to MAID violates the principle of autonomy, and, lacking scientific evidence, it does not clarify where the line is drawn between those who should be entitled to MAID and those who should not.","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"20-41"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Patient with diffuse large B-cell lymphoma: a good example of network in care.] 弥漫性大b细胞淋巴瘤：网络护理的一个很好的例子。

Recenti progressi in medicina Pub Date : 2025-01-01 DOI: 10.1701/4416.44128

Maria Chiara Tisi

引用次数: 0

[Effective treatment for Helicobacter pylori infection in adults: the 2024 American College of Gastroenterology guideline recommendations.] [有效治疗成人幽门螺旋杆菌感染：2024 年美国胃肠病学院指南建议]。

Recenti progressi in medicina Pub Date : 2024-12-01 DOI: 10.1701/4392.43919

Viviana Forte, Henry Barry, Peter K Kurotschka

引用次数: 0